Balanced news tone
News Sentiment
ANNX sentiment intelligence
Annexon Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+6.2% over one week, +23.1% over four weeks, trend inactive, and materially above fair value.
How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Annexon Inc (ANNX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Annexon Inc.'s (ANNX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and reports no data available for historical dividend payments or stock splits. The page primarily fo
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 00:40
- Source
- TradingKey
Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Annexon Inc (ANNX), covering its support, resistance, indicators, and moving averages. According to the analysis, relevant data for support and resistance have not been disclosed, while the technical indicators show mixed signals with
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 22:39
- Source
- TradingKey
Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares
Annexon, Inc. EVP Ted Yednock exercised stock options to acquire 30,646 common shares at an exercise price of $1.8501 per share on June 11, 2026. This transaction increased his direct ownership to 184,807 shares. The options were fully vested and exercisable, representing a routi
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 17 Jun 2026 08:39
- Source
- Stock Titan
Two new Annexon hires receive options on 705,000 shares
Annexon (Nasdaq: ANNX) has granted stock options for 705,000 shares to two new non-executive employees under its 2022 Employment Inducement Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.64 per share, a ten-year term, and a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 20:10
- Source
- Stock Titan
Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 13:06
- Source
- MarketBeat
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:07
- Source
- MarketBeat
Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 21:29
- Source
- MT Newswires
Annexon to Participate in Upcoming June Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 12:00
- Source
- GlobeNewswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 08:05
- Source
- MarketBeat
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Goldman Sachs Initiates Annexon at Neutral With $7 Price Target
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 12 May 2026 11:29
- Source
- MT Newswires
Goldman Sachs initiates Annexon Biosciences stock at Neutral on GA trial uncertainty
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- Investing.com
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- GlobeNewswire
Annexon CEO to speak May 13; webcast replay stays up 30 days
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Stock Titan
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 Apr 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 01 Apr 2026 07:00
- Source
- simplywall.st
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Investing News Network
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jan 2026 08:00
- Source
- Seeking Alpha
Annexon (ANNX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2025 17:19
- Source
- Stock Titan